A Phase 1 interventional study of LY3876602 and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
The aim of this study is to evaluate the safety, tolerability and PK of LY3876602 after administering it as single ascending doses and, following a data review, proceeding to multiple ascending doses in healthy participants. Blood tests will also be performed to check how much LY3876602 gets into the bloodstream and cerebrospinal fluid (CSF) and how long it takes the body to eliminate it.
Following the screening visit for Part A, the study will last up to approximately 20 weeks., and a subgroup of participants will consent to CSF collections The study will last up to approximately 28 weeks for Part B. All participants will consent to CSF collections.
Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Single ascending doses of LY3876602 administered intravenously (IV).
Drug: LY3876602
Placebo administered IV.
Drug: Placebo
Multiple ascending doses of LY3876602 will be administered intravenously (IV).
Drug: LY3876602
Placebo administered IV
Drug: Placebo
Administered IV.
Administered IV.
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline up to 28 weeks
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3876602
PK: AUC of LY3876602
Time frame: Predose up to 28 weeks
PK: Maximum Observed Drug Concentration (Cmax) of LY3876602
PK: Cmax of LY3876602
Time frame: Predose up to 28 weeks
PK: Half-life (t1/2) of LY3876602
PK: t1/2 of LY3876602
Time frame: Predose up to 28 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company